Slide 60 : ASCO 治疗 NSCLC 的 Guideline 二线治疗( Second-Line Therapy ) : 对一线治疗无效或进展的病人没有证据显示二 线治疗能延长病人的生存期。
基于6个网页-相关网页
Objective To evaluate the efficacy and toxicity of irinotecan combined with nedaplatin in second-line therapy of small-cell lung cancer.
目的观察伊立替康联合奈达铂二线治疗小细胞肺癌的疗效及毒副反应。
One caveat with this trial, as with any study of this kind, is that it does not take into account the possible impact of second-line therapy.
需要提醒的是,与任何一个同类的研究一样,此试验未考虑二线治疗的可能影响。
应用推荐